The U.S. is falling behind in converting scientific discoveries into medicines, with China now taking the lead in drug development despite America’s strong research quality. A Senate hearing on August 4 will address how to enhance U.S. biotechnology amid decreasing federal funding, including a significant cut of over 39% to the National Institutes of Health’s budget. Chinese firms excel in innovative drug production, leading to congressional scrutiny over the flow of American investments to China. The NIH cuts pose a critical threat to the drug development pipeline, raising concerns within the biotech industry about the future of American competitiveness.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://legis1.com/news/biotech-us-health-resilience-senate-panel-will
